Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn’s Disease With a Loss of Response

Abstract Background/Aims In patients receiving ustekinumab (UST) for treatment of Crohn’s disease, there is no proven strategy to enhance or re-capture response. We assessed the utility of UST intravenous (IV) reinduction (~6 mg/kg) to achieve clinical, biochemical and endoscopic response or remissi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the Canadian Association of Gastroenterology 2022-10, Vol.5 (5), p.208-213
Main Authors: Heron, Valerie, Li Fraine, Steven, Panaccione, Nicola, Restellini, Sophie, Germain, Pascale, Candido, Kristina, Bernstein, Charles N, Bessissow, Talat, Bitton, Alain, Chauhan, Usha K, Lakatos, Peter L, Marshall, John K, Michetti, Pierre, Seow, Cynthia H, Rosenfeld, Greg, Panaccione, Remo, Afif, Waqqas
Format: Article
Language:English
Subjects:
Original
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background/Aims In patients receiving ustekinumab (UST) for treatment of Crohn’s disease, there is no proven strategy to enhance or re-capture response. We assessed the utility of UST intravenous (IV) reinduction (~6 mg/kg) to achieve clinical, biochemical and endoscopic response or remission, in patients with partial or loss of response to UST maintenance therapy. Methods A multicentre, retrospective cohort study was performed. Adults who received an IV reinduction dose of UST for either partial response or secondary loss of response to UST were assessed. The primary outcome was clinical remission off corticosteroids (Harvey Bradshaw Index
ISSN:2515-2084
2515-2092
DOI:10.1093/jcag/gwac017